Literature DB >> 23551560

Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease.

M T Pellecchia1, G Santangelo, M Picillo, R Pivonello, K Longo, C Pivonello, C Vitale, M Amboni, A De Rosa, M Moccia, R Erro, G De Michele, L Santoro, A Colao, P Barone.   

Abstract

BACKGROUND AND
PURPOSE: Cognitive impairment is common in Parkinson's disease (PD), even in the early stages. We aimed to assess the relationship between insulin-like growth factor-1 (IGF-1) and cognitive functions in early, drug-naïve patients with PD.
METHODS: Serum IGF-1 was measured in 65 early, drug-naïve patients with PD that underwent a complete neuropsychological battery at baseline and after 2 years. Linear regression analysis was used to evaluate the relationships between neuropsychological scores and IGF-1. Repeated-measures anova was applied to assess changes in neuropsychological variables over time.
RESULTS: At baseline, IGF-1 levels were related to phonological fluency. At follow-up, IGF-1 levels were associated with the Rey auditory verbal learning test (RAVLT) - immediate and delayed recall, Frontal Assessment Battery, verbal span and Benton judgement of the line orientation test. Patients with low IGF-1 levels at baseline showed a significantly faster decline of performances than patients with high IGF-1 levels on immediate and delayed recall of the RAVLT and interference task of the Stroop test.
CONCLUSIONS: Low serum IGF-1 levels are related to poor performance on executive tasks in early, drug-naïve patients with PD, and may predict poor performance on attention/executive and verbal memory tasks after a 2-year follow-up.
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS.

Entities:  

Keywords:  cognitive functions; early Parkinson's disease; insulin-like growth factor-1

Mesh:

Substances:

Year:  2013        PMID: 23551560     DOI: 10.1111/ene.12137

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  17 in total

Review 1.  40 YEARS of IGF1: IGF1: the Jekyll and Hyde of the aging brain.

Authors:  Sriram Gubbi; Gabriela Farias Quipildor; Nir Barzilai; Derek M Huffman; Sofiya Milman
Journal:  J Mol Endocrinol       Date:  2018-05-08       Impact factor: 5.098

2.  Path analysis of biomarkers for cognitive decline in early Parkinson's disease.

Authors:  Dmitri K Gramotnev; Galina Gramotnev; Alexandra Gramotnev; Mathew J Summers
Journal:  PLoS One       Date:  2022-05-13       Impact factor: 3.752

3.  Changes of plasma cGP/IGF-1 molar ratio with age is associated with cognitive status of Parkinson disease.

Authors:  Dawei Fan; Toni Pitcher; John Dalrymple-Alford; Michael MacAskill; Tim Anderson; Jian Guan
Journal:  Alzheimers Dement (Amst)       Date:  2020-04-17

4.  The Association between IGF-1 Polymorphisms, IGF-1 Serum Levels, and Cognitive Functions in Healthy Adults: The Amsterdam Growth and Health Longitudinal Study.

Authors:  Carmilla M M Licht; Lise C van Turenhout; Jan Berend Deijen; Lando L J Koppes; Willem van Mechelen; Jos W R Twisk; Madeleine L Drent
Journal:  Int J Endocrinol       Date:  2014-07-10       Impact factor: 3.257

5.  Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.

Authors:  Felix P Bernhard; Sebastian Heinzel; Gerhard Binder; Karin Weber; Anja Apel; Benjamin Roeben; Christian Deuschle; Mirjam Maechtel; Tanja Heger; Susanne Nussbaum; Thomas Gasser; Walter Maetzler; Daniela Berg
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

6.  Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease.

Authors:  Marina Picillo; Rosario Pivonello; Gabriella Santangelo; Claudia Pivonello; Riccardo Savastano; Renata Auriemma; Marianna Amboni; Sara Scannapieco; Angela Pierro; Annamaria Colao; Paolo Barone; Maria Teresa Pellecchia
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

7.  Serum insulin-like growth factor 1 (IGF-1) in multiple sclerosis: relation to cognitive impairment and fatigue.

Authors:  Rania S Nageeb; Noha A Hashim; Amal Fawzy
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-09-15

8.  Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.

Authors:  Jose A Santiago; Judith A Potashkin
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

9.  Serum Insulin-Like Growth Factor-1 in Patients with De Novo, Drug Naïve Parkinson's Disease: A Meta-Analysis.

Authors:  Dun-Hui Li; Ya-Chao He; Thomas J Quinn; Jun Liu
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

10.  Evaluation of RNA Blood Biomarkers in the Parkinson's Disease Biomarkers Program.

Authors:  Jose A Santiago; Virginie Bottero; Judith A Potashkin
Journal:  Front Aging Neurosci       Date:  2018-05-29       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.